RAPT Therapeutics (NASDAQ:RAPT) PT Lowered to $2.00

RAPT Therapeutics (NASDAQ:RAPT) had its target price decreased by UBS Group from $10.00 to $2.00 in a research note published on Monday morning, Benzinga reports. UBS Group currently has a neutral rating on the stock.

RAPT has been the subject of a number of other research reports. HC Wainwright reissued a neutral rating on shares of RAPT Therapeutics in a report on Tuesday, August 20th. Wolfe Research reiterated a peer perform rating on shares of RAPT Therapeutics in a research note on Tuesday, May 14th. Nine equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of Hold and an average target price of $20.43.

RAPT Therapeutics Stock Performance

NASDAQ:RAPT opened at $1.93 on Monday. The stock has a 50 day simple moving average of $2.66 and a 200 day simple moving average of $5.09. The stock has a market cap of $67.36 million, a P/E ratio of -0.63 and a beta of 0.34. RAPT Therapeutics has a 1-year low of $1.77 and a 1-year high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.03. As a group, sell-side analysts forecast that RAPT Therapeutics will post -2.73 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its holdings in shares of RAPT Therapeutics by 65.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,602 shares of the company’s stock valued at $59,000 after purchasing an additional 2,621 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in RAPT Therapeutics in the first quarter valued at about $97,000. XTX Topco Ltd bought a new position in RAPT Therapeutics in the second quarter valued at about $108,000. Hennion & Walsh Asset Management Inc. grew its position in RAPT Therapeutics by 8.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock valued at $148,000 after acquiring an additional 3,824 shares during the last quarter. Finally, EntryPoint Capital LLC bought a new position in shares of RAPT Therapeutics in the first quarter worth about $161,000. 99.09% of the stock is owned by institutional investors.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.